ArticleFrontiers in oncology2022
Targeting ALK in Neuroendocrine Tumors of the Lung.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).Cancer immunology, immunotherapy : CII · 2026Trial
- De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.Medical sciences (Basel, Switzerland) · 2026Article
- Comparison of Amplicon-Based Next-Generation Sequencing Testing and Immunohistochemical Staining in DetectingCancers · 2026Article
- Identification of Actionable Gene Variants in Pulmonary Large-Cell Neuroendocrine Carcinoma: A Real-World Analysis of a Polish Cohort.International journal of molecular sciences · 2026Article
- Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.Clinical lung cancer · 2025Article
- Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with AdvancedInternational journal of molecular sciences · 2025Review
- Review
- [A Case of Multiple Primary Pulmonary Neuroendocrine Carcinoma with EML4-ALK Fusion Gene Positive].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44-ALK Fusion: A Case Report and Literature Review.The clinical respiratory journal · 2024Review
- Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective.Frontiers in pharmacology · 2024Article
- Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features.Journal of pathology and translational medicine · 2024Article
- Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report.JTO clinical and research reports · 2023Article
- EML4-ALK rearrangement of lung large cell neuroendocrine carcinoma: a case report.Annals of translational medicine · 2023Article
- Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.Frontiers in oncology · 2023Article
- Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.Cold Spring Harbor molecular case studies · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: To illustrate the clinical impact of molecular characterization in LCNECs, we report the disease course in three patients with Results: Within the retrospective cohort, ALK IHC was positive in 35 out of 362 (9.7%) evaluable samples. FISH was positive in 3 out of the 28 (10.7%) evaluable cases: 2 with atypical carcinoids and 1 with LCNEC. Additionally, the 3 index cases showed positive ALK IHC, which was confirmed by NGS. Within the retrospective cohort, NGS confirmed the presence of an Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.